SEL ICB Lambeth Community Denosumab Service

{
  "id": "071732-2026",
  "tag": [
    "tenderUpdate"
  ],
  "date": "2026-07-29T14:05:03+01:00",
  "ocid": "ocds-h6vhtk-068c80",
  "buyer": {
    "id": "GB-FTS-60642",
    "name": "NHS South East London Integrated Care Board"
  },
  "tender": {
    "id": "ocds-h6vhtk-068c80",
    "title": "SEL ICB Lambeth Community Denosumab Service",
    "amendments": [
      {
        "id": "5",
        "description": "This is a Provider Selection Regime (PSR) confirmation of contract award notice. This contract has been awarded under the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act 2023 do not apply to this award. This contract has now been formally awarded using direct award process C.",
        "unstructuredChanges": [
          {
            "where": {
              "label": "Description of the procurement",
              "section": "II.2.4"
            },
            "newValue": {
              "text": "This notice relates to the Lambeth Community Denosumab Service and is an intention to award a contract to the existing provider via Direct Award Process C.\nThe service provides a community-based shared care pathway for patients prescribed denosumab 60mg/ml for the treatment of osteoporosis. Patients remain under the clinical responsibility of secondary care within South East London, in accordance with the South East London Shared Care Agreement for Denosumab. Secondary care will identify and refer a cohort of clinically appropriate patients for management in the community setting. The Provider will be responsible for delivering the community service, including required blood monitoring, prescribing support, and administration of denosumab injections at clinically appropriate intervals. The service is available to patients referred by secondary care who are registered with a GP in Lambeth or are Lambeth residents and who meet the eligibility criteria set out in the contract and Shared Care Agreement.\nThe services under this contract are intended to be provided from 01 June 2026 for an initial term of 6 months, with the option for the Commissioner to extend the contract once by a further 6 months. Should the extension be exercised, the contract term may continue until 31 May 2027.\nThis is a direct award with no competition under the Provider Selection Regime (PSR) - Direct Award Process C. As such, no award criteria were applied.\nThe contracting authority has determined that the existing provider will be awarded the contract on the basis that:\nThe current provider is delivering the service to a satisfactory standard. There are no proposed changes to the existing contract terms. Continuity of care is essential for this patient cohort\nThe provider continues to meet all relevant clinical, quality, and service requirements. The decision is made in accordance with PSR requirements for Direct Award Process C."
            },
            "oldValue": {
              "text": ""
            }
          },
          {
            "where": {
              "section": "VI.3"
            },
            "newValue": {
              "text": "This is a Provider Selection Regime (PSR) confirmation of contract award notice. This contract has been awarded under the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act 2023 do not apply to this award. This contract has now been formally awarded using direct award process C.\nThis contract is for Lambeth Community Denosumab Service.\nThe services under this contract are intended to be provided from 01 June 2026 for an initial term of 6 months, with the option for the Commissioner to extend the contract once by a further 6 months. Should the extension be exercised, the contract term may continue until 31 May 2027.\nThe total lifetime value of the contract, excluding VAT, is £49,140 This comprises:\n6 months 1st June 2026- 30 November 2026 with an optional extension for a further 6 months until the 31st May 2027.\nDuring the standstill period, no formal review process was undertaken.\nThe award decision was made by the following individuals:\nJenny Sivaganam, Assistant Director, SEL Medicines Optimisation, NHS SEL ICB (Lambeth)\nLambeth Together Planning and Finance Group 23 March 2026\nLambeth Together Senior Management Team 31 March 2026\nNo conflicts of interest, either declared or potential, were identified in relation to the individuals involved in the decision-making process. Accordingly, no conflict management actions were required."
            },
            "oldValue": {
              "text": ""
            }
          }
        ]
      }
    ],
    "legalBasis": {
      "id": "32014L0024",
      "scheme": "CELEX"
    },
    "description": "Provision of a community-based shared care service for the administration and monitoring of denosumab 60mg/ml for osteoporosis. The service will support patients in Lambeth (or registered with a Lambeth GP) who have been identified by secondary care as clinically appropriate for treatment in the community. The Provider will deliver blood monitoring, prescribing support, and timely administration of injections in accordance with the South East London Shared Care Agreement, while clinical responsibility remains with secondary care.",
    "classification": {
      "id": "85141000",
      "scheme": "CPV",
      "description": "Services provided by medical personnel"
    },
    "mainProcurementCategory": "services"
  },
  "parties": [
    {
      "id": "GB-FTS-60642",
      "name": "NHS South East London Integrated Care Board",
      "roles": [
        "buyer"
      ],
      "address": {
        "region": "UKI45",
        "locality": "London",
        "postalCode": "SE1 2TZ",
        "countryName": "United Kingdom",
        "streetAddress": "160 Tooley Street"
      },
      "details": {
        "url": "https://www.selondonics.org/icb/",
        "buyerProfile": "https://www.selondonics.org/icb/"
      },
      "identifier": {
        "legalName": "NHS South East London Integrated Care Board",
        "noIdentifierRationale": "notOnAnyRegister"
      },
      "contactPoint": {
        "email": "hub.queries@nhs.net"
      }
    }
  ],
  "language": "en",
  "initiationType": "tender"
}

{
  "id": "063922-2026",
  "tag": [
    "tenderUpdate"
  ],
  "date": "2026-07-08T09:13:17+01:00",
  "ocid": "ocds-h6vhtk-068c80",
  "buyer": {
    "id": "GB-FTS-60642",
    "name": "NHS South East London Integrated Care Board"
  },
  "tender": {
    "id": "ocds-h6vhtk-068c80",
    "title": "SEL ICB Lambeth Community Denosumab Service",
    "amendments": [
      {
        "id": "4",
        "description": "This is a Provider Selection Regime (PSR) confirmation of contract award notice. This contract has been awarded under the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act 2023 do not apply to this award. This contract has now been formally awarded using direct award process C.\nThe contract for Community Denosumab Service was awarded on 19 May 2026.\nThe services under this contract are intended to be provided from 01 July 2026 to 30 June 2028, with the option to extend for a further 1 + 1 years at the sole discretion of the contracting authority. Should both optional extensions be exercised, the contract term will run until 30 June 2030.\nThe total lifetime value of the contract, excluding VAT, is £2,311,995. This comprises:\nYear 1: £611,374\nYears 2-4: £566,874 per annum\nThe values for Years 3 and 4 are indicative and based on projected activity levels, and are subject to review and agreement prior to extension.\nDuring the standstill period, no formal review process was undertaken.\nThe award decision was made by the following individuals:\nJenny Sivaganam (Assistant Director, SEL Medicines Optimisation, NHS SEL ICB (Lambeth))\nAndrew Eyres (Place Executive Lead for Lambeth and Corporate Director, Integrated Health and Adult Social Care, NHS SEL ICB)\nMike Fox (Director of Finance, NHS SEL ICB)\nNo conflicts of interest, either declared or potential, were identified in relation to the individuals involved in the decision-making process. Accordingly, no conflict management actions were required."
      }
    ],
    "legalBasis": {
      "id": "32014L0024",
      "scheme": "CELEX"
    },
    "description": "Provision of a community-based shared care service for the administration and monitoring of denosumab 60mg/ml for osteoporosis. The service will support patients in Lambeth (or registered with a Lambeth GP) who have been identified by secondary care as clinically appropriate for treatment in the community. The Provider will deliver blood monitoring, prescribing support, and timely administration of injections in accordance with the South East London Shared Care Agreement, while clinical responsibility remains with secondary care.",
    "classification": {
      "id": "85141000",
      "scheme": "CPV",
      "description": "Services provided by medical personnel"
    },
    "mainProcurementCategory": "services"
  },
  "parties": [
    {
      "id": "GB-FTS-60642",
      "name": "NHS South East London Integrated Care Board",
      "roles": [
        "buyer"
      ],
      "address": {
        "region": "UKI45",
        "locality": "London",
        "postalCode": "SE1 2TZ",
        "countryName": "United Kingdom",
        "streetAddress": "160 Tooley Street"
      },
      "details": {
        "url": "https://www.selondonics.org/icb/",
        "buyerProfile": "https://www.selondonics.org/icb/"
      },
      "identifier": {
        "legalName": "NHS South East London Integrated Care Board",
        "noIdentifierRationale": "notOnAnyRegister"
      },
      "contactPoint": {
        "email": "hub.queries@nhs.net"
      }
    }
  ],
  "language": "en",
  "initiationType": "tender"
}

{
  "id": "063617-2026",
  "tag": [
    "tenderUpdate"
  ],
  "date": "2026-07-07T12:46:36+01:00",
  "ocid": "ocds-h6vhtk-068c80",
  "buyer": {
    "id": "GB-FTS-60642",
    "name": "NHS South East London Integrated Care Board"
  },
  "tender": {
    "id": "ocds-h6vhtk-068c80",
    "title": "SEL ICB Lambeth Community Denosumab Service",
    "amendments": [
      {
        "id": "3",
        "description": "This is a Provider Selection Regime (PSR) confirmation of contract award notice. This contract has been awarded under the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act 2023 do not apply to this award. This contract has now been formally awarded using direct award process C.\nThe contract for Community Based Cardiology Diagnostic Services (Electrocardiogram and Blood Pressure Monitoring) (Contract Reference: 202607SELICB (LAMBETH) XEC) was awarded on 19 May 2026.\nThe services under this contract are intended to be provided from 01 July 2026 to 30 June 2028, with the option to extend for a further 1 + 1 years at the sole discretion of the contracting authority. Should both optional extensions be exercised, the contract term will run until 30 June 2030.\nThe total lifetime value of the contract, excluding VAT, is £2,311,995. This comprises:\nYear 1: £611,374\nYears 2-4: £566,874 per annum\nThe values for Years 3 and 4 are indicative and based on projected activity levels, and are subject to review and agreement prior to extension.\nDuring the standstill period, no formal review process was undertaken.\nThe award decision was made by the following individuals:\nJenny Sivaganam (Assistant Director, SEL Medicines Optimisation, NHS SEL ICB (Lambeth))\nAndrew Eyres (Place Executive Lead for Lambeth and Corporate Director, Integrated Health and Adult Social Care, NHS SEL ICB)\nMike Fox (Director of Finance, NHS SEL ICB)\nNo conflicts of interest, either declared or potential, were identified in relation to the individuals involved in the decision-making process. Accordingly, no conflict management actions were required."
      }
    ],
    "legalBasis": {
      "id": "32014L0024",
      "scheme": "CELEX"
    },
    "description": "Provision of a community-based shared care service for the administration and monitoring of denosumab 60mg/ml for osteoporosis. The service will support patients in Lambeth (or registered with a Lambeth GP) who have been identified by secondary care as clinically appropriate for treatment in the community. The Provider will deliver blood monitoring, prescribing support, and timely administration of injections in accordance with the South East London Shared Care Agreement, while clinical responsibility remains with secondary care.",
    "classification": {
      "id": "85141000",
      "scheme": "CPV",
      "description": "Services provided by medical personnel"
    },
    "mainProcurementCategory": "services"
  },
  "parties": [
    {
      "id": "GB-FTS-60642",
      "name": "NHS South East London Integrated Care Board",
      "roles": [
        "buyer"
      ],
      "address": {
        "region": "UKI45",
        "locality": "London",
        "postalCode": "SE1 2TZ",
        "countryName": "United Kingdom",
        "streetAddress": "160 Tooley Street"
      },
      "details": {
        "url": "https://www.selondonics.org/icb/",
        "buyerProfile": "https://www.selondonics.org/icb/"
      },
      "identifier": {
        "legalName": "NHS South East London Integrated Care Board",
        "noIdentifierRationale": "notOnAnyRegister"
      },
      "contactPoint": {
        "email": "hub.queries@nhs.net"
      }
    }
  ],
  "language": "en",
  "initiationType": "tender"
}

{
  "id": "038537-2026",
  "tag": [
    "tenderUpdate"
  ],
  "date": "2026-04-28T12:48:26+01:00",
  "ocid": "ocds-h6vhtk-068c80",
  "buyer": {
    "id": "GB-NHS-QKK",
    "name": "NHS South East London Integrated Care Board"
  },
  "tender": {
    "id": "ocds-h6vhtk-068c80",
    "title": "SEL ICB Lambeth Community Denosumab Service",
    "amendments": [
      {
        "id": "2",
        "unstructuredChanges": [
          {
            "where": {
              "label": "Additional information",
              "section": "VI.3"
            },
            "newValue": {
              "text": "This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act 2023 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to decision makers by Tuesday 12th May 2026.\nThis contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.\nWritten representations should be sent to: hub.psrrepresentation@nhs.net\nAward Decision makers: Andrew Eyres- Corporate Director, Integrated Health and Adult Social Care\nThere was no conflict of interest identified in the decision-making process.\nEvaluation Criteria and Weighting\nScoring from 0-4, with percentage allocation based on the importance of the criteria in the service requirement. Key criteria:\nQuality and Innovation: 20%\nValue for Money: 25%\nIntegration, Collaboration and Service Sustainability: 20%\nImproving Access, Reducing Health Inequalities and Facilitating Choice: 25%\nSocial Value: 10%\nThe criteria were applied with their respective weightings as specified, with scoring against a number of sub-categories for each criterion. An assessment against current and future performance for these individual sub-categories was undertaken, resulting in a combined overall score out of 100%.\nThe publication of this notice marks the start of the standstill period, commencing on Thursday 30th April 2026 ending at 23:59 on Tuesday 12 May 2026.\nRepresentations by providers must be submitted by 23:59 on Tuesday 12 May 2026 to: hub.psrrepresentation@nhs.net and must be made to the decision makers within this period.\nThe contract may be formally awarded on Wednesday 13 May 2026, provided no representations are received, or once any representations have been addressed.\nThis contract has not yet formally been awarded; this notice serves as an intention to award under the Provider Selection Regime (PSR).\nNo conflicts of interest were identified in the decision-making process.\nDecision Makers and Dates of Decision\nThe decision to proceed with the intention to award was made by:\nAndrew Eyres- Corporate Director, Integrated Health and Adult Social Care\nLambeth Together Planning and Finance Group - 23 March 2026\nLambeth Together Senior Management Team - 31 March 2026\nRationale for Selection of Current Provider\nThe current provider has demonstrated sustained high-quality performance and value for money, including:\nMaintaining 100% performance across key service standards, including:\n-Provision of service to all appropriately referred patients\n-Contacting patients within 72 hours of referral from secondary care\n-Issuing patient reminder cards and information leaflets\n-Providing consistent feedback from service users and referring acute trusts\n-Reporting 0% near misses or incidents from both the provider and acute trust\n-Effective financial management, remaining within the agreed budget\n-Delivery in line with NICE TA204 (Denosumab for the prevention of osteoporotic fractures in postmenopausal women)\n-Alignment with the South East London Osteoporosis Pathway and the South East London Shared Care Agreement for Denosumab 60mg/ml\n-Supporting care closer to home and improved patient experience through community-based administration of treatment\n-Sustained achievement of ≥95% across key performance indicators, including:\n-Timely patient contact within 72 hours\n-Provision of patient information materials\n-Service user and referrer feedback mechanisms\n-Incident reporting compliance\n-Annual patient satisfaction feedback demonstrating good service experience"
            },
            "oldValue": {
              "text": "This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act 2023 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to decision makers by Tuesday 12th May 2026.\nThis contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.\nWritten representations should be sent to: hub.psrrepresentation@nhs.net\nAward Decision makers: Andrew Eyres- Corporate Director, Integrated Health and Adult Social Care\nThere was no conflict of interest identified in the decision-making process.\nEvaluation Criteria and Weighting\nScoring from 0-4, with percentage allocation based on the importance of the criteria in the service requirement. Key criteria:\nQuality and Innovation: 20%\nValue for Money: 25%\nIntegration, Collaboration and Service Sustainability: 20%\nImproving Access, Reducing Health Inequalities and Facilitating Choice: 25%\nSocial Value: 10%\nThe criteria were applied with their respective weightings as specified, with scoring against a number of sub-categories for each criterion. An assessment against current and future performance for these individual sub-categories was undertaken, resulting in a combined overall score out of 100%.\nThe publication of this notice marks the start of the standstill period, commencing on Wednesday 30th April 2026 ending at 23:59 on Tuesday 12 May 2026.\nRepresentations by providers must be submitted by 23:59 on Tuesday 12 May 2026 to: hub.psrrepresentation@nhs.net\nand must be made to the decision makers within this period.\nThe contract may be formally awarded on Wednesday 13 May 2026, provided no representations are received, or once any representations have been addressed.\nThis contract has not yet formally been awarded; this notice serves as an intention to award under the Provider Selection Regime (PSR).\nNo conflicts of interest were identified in the decision-making process.\nDecision Makers and Dates of Decision\nThe decision to proceed with the intention to award was made by:\nAndrew Eyres- Corporate Director, Integrated Health and Adult Social Care\nLambeth Together Planning and Finance Group - 23 March 2026\nLambeth Together Senior Management Team - 31 March 2026\nRationale for Selection of Current Provider\nThe current provider has demonstrated sustained high-quality performance and value for money, including:\nMaintaining 100% performance across key service standards, including:\n-Provision of service to all appropriately referred patients\n-Contacting patients within 72 hours of referral from secondary care\n-Issuing patient reminder cards and information leaflets\n-Providing consistent feedback from service users and referring acute trusts\n-Reporting 0% near misses or incidents from both the provider and acute trust\n-Effective financial management, remaining within the agreed budget\n-Delivery in line with NICE TA204 (Denosumab for the prevention of osteoporotic fractures in postmenopausal women)\n-Alignment with the South East London Osteoporosis Pathway and the South East London Shared Care Agreement for Denosumab 60mg/ml\n-Supporting care closer to home and improved patient experience through community-based administration of treatment\n-Sustained achievement of ≥95% across key performance indicators, including:\n-Timely patient contact within 72 hours\n-Provision of patient information materials\n-Service user and referrer feedback mechanisms\n-Incident reporting compliance\n-Annual patient satisfaction feedback demonstrating good service experience"
            }
          },
          {
            "where": {
              "label": "Precise information on deadline(s) for review procedures",
              "section": "VI.4.3."
            },
            "newValue": {
              "text": "The publication of this notice marks the start of the standstill period, commencing on Thursday 30th April 2026 ending at 23:59 on Tuesday 12 May 2026.\nRepresentations by providers must be submitted by 23:59 on Tuesday 12 May 2026 to: hub.psrrepresentation@nhs.net\nand must be made to the decision makers within this period.\nThe contract may be formally awarded on Wednesday 13 May 2026, provided no representations are received, or once any representations have been addressed."
            },
            "oldValue": {
              "text": "The publication of this notice marks the start of the standstill period, commencing on Wednesday 30th April 2026 ending at 23:59 on Tuesday 12 May 2026.\nRepresentations by providers must be submitted by 23:59 on Tuesday 12 May 2026 to: hub.psrrepresentation@nhs.net\nand must be made to the decision makers within this period.\nThe contract may be formally awarded on Wednesday 13 May 2026, provided no representations are received, or once any representations have been addressed."
            }
          }
        ]
      }
    ],
    "legalBasis": {
      "id": "32014L0024",
      "scheme": "CELEX"
    },
    "description": "Provision of a community-based shared care service for the administration and monitoring of denosumab 60mg/ml for osteoporosis. The service will support patients in Lambeth (or registered with a Lambeth GP) who have been identified by secondary care as clinically appropriate for treatment in the community. The Provider will deliver blood monitoring, prescribing support, and timely administration of injections in accordance with the South East London Shared Care Agreement, while clinical responsibility remains with secondary care.",
    "classification": {
      "id": "85141000",
      "scheme": "CPV",
      "description": "Services provided by medical personnel"
    },
    "mainProcurementCategory": "services"
  },
  "parties": [
    {
      "id": "GB-NHS-QKK",
      "name": "NHS South East London Integrated Care Board",
      "roles": [
        "buyer"
      ],
      "address": {
        "region": "UKI45",
        "locality": "London",
        "postalCode": "SE1 2TZ",
        "countryName": "United Kingdom",
        "streetAddress": "160 Tooley Street"
      },
      "details": {
        "url": "https://www.selondonics.org/icb/",
        "buyerProfile": "https://www.selondonics.org/icb/"
      },
      "identifier": {
        "id": "QKK",
        "scheme": "GB-NHS",
        "legalName": "NHS South East London Integrated Care Board"
      },
      "contactPoint": {
        "email": "hub.queries@nhs.net"
      }
    }
  ],
  "language": "en",
  "initiationType": "tender"
}

{
  "id": "038498-2026",
  "tag": [
    "tenderUpdate"
  ],
  "date": "2026-04-28T12:15:36+01:00",
  "ocid": "ocds-h6vhtk-068c80",
  "buyer": {
    "id": "GB-NHS-QKK",
    "name": "NHS South East London Integrated Care Board"
  },
  "tender": {
    "id": "ocds-h6vhtk-068c80",
    "title": "SEL ICB Lambeth Community Denosumab Service",
    "amendments": [
      {
        "id": "1",
        "unstructuredChanges": [
          {
            "where": {
              "label": "VI.3 Additional information",
              "section": "VI.3"
            },
            "newValue": {
              "text": "This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act 2023 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to decision makers by Tuesday 12th May 2026.\nThis contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.\nWritten representations should be sent to: hub.psrrepresentation@nhs.net\nAward Decision makers: Andrew Eyres- Corporate Director, Integrated Health and Adult Social Care\nThere was no conflict of interest identified in the decision-making process.\nEvaluation Criteria and Weighting\nScoring from 0-4, with percentage allocation based on the importance of the criteria in the service requirement. Key criteria:\nQuality and Innovation: 20%\nValue for Money: 25%\nIntegration, Collaboration and Service Sustainability: 20%\nImproving Access, Reducing Health Inequalities and Facilitating Choice: 25%\nSocial Value: 10%\nThe criteria were applied with their respective weightings as specified, with scoring against a number of sub-categories for each criterion. An assessment against current and future performance for these individual sub-categories was undertaken, resulting in a combined overall score out of 100%.\nThe publication of this notice marks the start of the standstill period, commencing on Thursday 30th April 2026 ending at 23:59 on Tuesday 12 May 2026.\nRepresentations by providers must be submitted by 23:59 on Tuesday 12 May 2026 to: hub.psrrepresentation@nhs.net\nand must be made to the decision makers within this period.\nThe contract may be formally awarded on Wednesday 13 May 2026, provided no representations are received, or once any representations have been addressed.\nThis contract has not yet formally been awarded; this notice serves as an intention to award under the Provider Selection Regime (PSR).\nNo conflicts of interest were identified in the decision-making process.\nDecision Makers and Dates of Decision\nThe decision to proceed with the intention to award was made by:\nAndrew Eyres- Corporate Director, Integrated Health and Adult Social Care\nLambeth Together Planning and Finance Group - 23 March 2026\nLambeth Together Senior Management Team - 31 March 2026\nRationale for Selection of Current Provider\nThe current provider has demonstrated sustained high-quality performance and value for money, including:\nMaintaining 100% performance across key service standards, including:\n-Provision of service to all appropriately referred patients\n-Contacting patients within 72 hours of referral from secondary care\n-Issuing patient reminder cards and information leaflets\n-Providing consistent feedback from service users and referring acute trusts\n-Reporting 0% near misses or incidents from both the provider and acute trust\n-Effective financial management, remaining within the agreed budget\n-Delivery in line with NICE TA204 (Denosumab for the prevention of osteoporotic fractures in postmenopausal women)\n-Alignment with the South East London Osteoporosis Pathway and the South East London Shared Care Agreement for Denosumab 60mg/ml\n-Supporting care closer to home and improved patient experience through community-based administration of treatment\n-Sustained achievement of ≥95% across key performance indicators, including:\n-Timely patient contact within 72 hours\n-Provision of patient information materials\n-Service user and referrer feedback mechanisms\n-Incident reporting compliance\n-Annual patient satisfaction feedback demonstrating good service experience"
            },
            "oldValue": {
              "text": "This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act 2023 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to decision makers by Tuesday 12th May 2026.\nThis contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.\nWritten representations should be sent to: hub.psrrepresentation@nhs.net\nAward Decision makers: Andrew Eyres- Corporate Director, Integrated Health and Adult Social Care\nThere was no conflict of interest identified in the decision-making process.\nEvaluation Criteria and Weighting\nScoring from 0-4, with percentage allocation based on the importance of the criteria in the service requirement. Key criteria:\nQuality and Innovation: 20%\nValue for Money: 25%\nIntegration, Collaboration and Service Sustainability: 20%\nImproving Access, Reducing Health Inequalities and Facilitating Choice: 25%\nSocial Value: 10%\nThe criteria were applied with their respective weightings as specified, with scoring against a number of sub-categories for each criterion. An assessment against current and future performance for these individual sub-categories was undertaken, resulting in a combined overall score out of 100%.\nThe publication of this notice marks the start of the standstill period, commencing on Wednesday 30th April 2026 ending at 23:59 on Tuesday 12 May 2026.\nRepresentations by providers must be submitted by 23:59 on Tuesday 12 May 2026 to: hub.psrrepresentation@nhs.net\nand must be made to the decision makers within this period.\nThe contract may be formally awarded on Wednesday 13 May 2026, provided no representations are received, or once any representations have been addressed.\nThis contract has not yet formally been awarded; this notice serves as an intention to award under the Provider Selection Regime (PSR).\nNo conflicts of interest were identified in the decision-making process.\nDecision Makers and Dates of Decision\nThe decision to proceed with the intention to award was made by:\nAndrew Eyres- Corporate Director, Integrated Health and Adult Social Care\nLambeth Together Planning and Finance Group - 23 March 2026\nLambeth Together Senior Management Team - 31 March 2026\nRationale for Selection of Current Provider\nThe current provider has demonstrated sustained high-quality performance and value for money, including:\nMaintaining 100% performance across key service standards, including:\n-Provision of service to all appropriately referred patients\n-Contacting patients within 72 hours of referral from secondary care\n-Issuing patient reminder cards and information leaflets\n-Providing consistent feedback from service users and referring acute trusts\n-Reporting 0% near misses or incidents from both the provider and acute trust\n-Effective financial management, remaining within the agreed budget\n-Delivery in line with NICE TA204 (Denosumab for the prevention of osteoporotic fractures in postmenopausal women)\n-Alignment with the South East London Osteoporosis Pathway and the South East London Shared Care Agreement for Denosumab 60mg/ml\n-Supporting care closer to home and improved patient experience through community-based administration of treatment\n-Sustained achievement of ≥95% across key performance indicators, including:\n-Timely patient contact within 72 hours\n-Provision of patient information materials\n-Service user and referrer feedback mechanisms\n-Incident reporting compliance\n-Annual patient satisfaction feedback demonstrating good service experience"
            }
          },
          {
            "where": {
              "label": "Precise information on deadline(s) for review procedures",
              "section": "VI.4.3."
            },
            "newValue": {
              "text": "The publication of this notice marks the start of the standstill period, commencing on Thursday 30th April 2026 ending at 23:59 on Tuesday 12 May 2026.\nRepresentations by providers must be submitted by 23:59 on Tuesday 12 May 2026 to: hub.psrrepresentation@nhs.net\nand must be made to the decision makers within this period.\nThe contract may be formally awarded on Wednesday 13 May 2026, provided no representations are received, or once any representations have been addressed."
            },
            "oldValue": {
              "text": "The publication of this notice marks the start of the standstill period, commencing on Wednesday 30th April 2026 ending at 23:59 on Tuesday 12 May 2026.\nRepresentations by providers must be submitted by 23:59 on Tuesday 12 May 2026 to: hub.psrrepresentation@nhs.net\nand must be made to the decision makers within this period.\nThe contract may be formally awarded on Wednesday 13 May 2026, provided no representations are received, or once any representations have been addressed."
            }
          }
        ]
      }
    ],
    "legalBasis": {
      "id": "32014L0024",
      "scheme": "CELEX"
    },
    "description": "Provision of a community-based shared care service for the administration and monitoring of denosumab 60mg/ml for osteoporosis. The service will support patients in Lambeth (or registered with a Lambeth GP) who have been identified by secondary care as clinically appropriate for treatment in the community. The Provider will deliver blood monitoring, prescribing support, and timely administration of injections in accordance with the South East London Shared Care Agreement, while clinical responsibility remains with secondary care.",
    "classification": {
      "id": "85141000",
      "scheme": "CPV",
      "description": "Services provided by medical personnel"
    },
    "mainProcurementCategory": "services"
  },
  "parties": [
    {
      "id": "GB-NHS-QKK",
      "name": "NHS South East London Integrated Care Board",
      "roles": [
        "buyer"
      ],
      "address": {
        "region": "UKI45",
        "locality": "London",
        "postalCode": "SE1 2TZ",
        "countryName": "United Kingdom",
        "streetAddress": "160 Tooley Street"
      },
      "details": {
        "url": "https://www.selondonics.org/icb/",
        "buyerProfile": "https://www.selondonics.org/icb/"
      },
      "identifier": {
        "id": "QKK",
        "scheme": "GB-NHS",
        "legalName": "NHS South East London Integrated Care Board"
      },
      "contactPoint": {
        "email": "hub.queries@nhs.net"
      }
    }
  ],
  "language": "en",
  "initiationType": "tender"
}

{
  "id": "038464-2026",
  "tag": [
    "award",
    "contract"
  ],
  "bids": {
    "statistics": [
      {
        "id": "1",
        "value": 1,
        "measure": "bids",
        "relatedLot": "1"
      }
    ]
  },
  "date": "2026-04-28T11:40:43+01:00",
  "ocid": "ocds-h6vhtk-068c80",
  "buyer": {
    "id": "GB-NHS-QKK",
    "name": "NHS South East London Integrated Care Board"
  },
  "awards": [
    {
      "id": "038464-2026-1",
      "status": "active",
      "suppliers": [
        {
          "id": "GB-NHS-CQC",
          "name": "Lambeth Healthcare Ltd"
        }
      ],
      "relatedLots": [
        "1"
      ]
    }
  ],
  "tender": {
    "id": "ocds-h6vhtk-068c80",
    "lots": [
      {
        "id": "1",
        "status": "cancelled",
        "options": {
          "description": "The Contracting Authority may, at its discretion, may extend the contract for a further period of up to 6 months."
        },
        "hasOptions": true,
        "description": "This notice relates to the Lambeth Community Denosumab Service and is an intention to award a contract to the existing provider via Direct Award Process C.\nThe service provides a community-based shared care pathway for patients prescribed denosumab 60mg/ml for the treatment of osteoporosis. Patients remain under the clinical responsibility of secondary care within South East London, in accordance with the South East London Shared Care Agreement for Denosumab. Secondary care will identify and refer a cohort of clinically appropriate patients for management in the community setting. The Provider will be responsible for delivering the community service, including required blood monitoring, prescribing support, and administration of denosumab injections at clinically appropriate intervals. The service is available to patients referred by secondary care who are registered with a GP in Lambeth or are Lambeth residents and who meet the eligibility criteria set out in the contract and Shared Care Agreement.\nThe estimated contract value is £49,140 per annum. The contract duration is 6 months from 01/06/2026 to 30/11/2026, with an option to extend for a further 6 months at the discretion of the Authority, up to 31/05/2027.\nThis is a direct award with no competition under the Provider Selection Regime (PSR) - Direct Award Process C. As such, no award criteria were applied.\nThe contracting authority has determined that the existing provider will be awarded the contract on the basis that:\nThe current provider is delivering the service to a satisfactory standard. There are no proposed changes to the existing contract terms. Continuity of care is essential for this patient cohort\nThe provider continues to meet all relevant clinical, quality, and service requirements. The decision is made in accordance with PSR requirements for Direct Award Process C. Additional information: Procurement Route\nThis contract is intended to be awarded under the Provider Selection Regime (PSR) - Direct Award Process C.\nRationale for Direct Award\nThe current provider is delivering the service to a satisfactory standard, and there are no proposed changes to the existing contract terms. Continuity of care is essential for this patient cohort.\nThe provider continues to meet all relevant clinical, quality, and service requirements.\nDecision\nThe Contracting Authority intends to award the contract to the existing provider in accordance with PSR Direct Award Process C.",
        "awardCriteria": {
          "criteria": [
            {
              "name": "Award Criteria: Cost & Quality criteria Cost & Quality criterion: the existing provider is satisfying the original contract and will likely satisfy the proposed contract to a sufficient standard Weighting: 100%",
              "type": "cost",
              "description": "100%"
            }
          ]
        }
      }
    ],
    "items": [
      {
        "id": "1",
        "relatedLot": "1",
        "deliveryLocation": {
          "description": "Community-based healthcare settings within Lambeth; patients registered with Lambeth GP practices or resident in Lambeth."
        },
        "deliveryAddresses": [
          {
            "region": "UKI45"
          }
        ],
        "additionalClassifications": [
          {
            "id": "85141000",
            "scheme": "CPV",
            "description": "Services provided by medical personnel"
          }
        ]
      }
    ],
    "title": "SEL ICB Lambeth Community Denosumab Service",
    "status": "complete",
    "coveredBy": [
      "GPA"
    ],
    "legalBasis": {
      "id": "32014L0024",
      "scheme": "CELEX"
    },
    "description": "Provision of a community-based shared care service for the administration and monitoring of denosumab 60mg/ml for osteoporosis. The service will support patients in Lambeth (or registered with a Lambeth GP) who have been identified by secondary care as clinically appropriate for treatment in the community. The Provider will deliver blood monitoring, prescribing support, and timely administration of injections in accordance with the South East London Shared Care Agreement, while clinical responsibility remains with secondary care.",
    "reviewDetails": "The publication of this notice marks the start of the standstill period, commencing on Wednesday 30th April 2026 ending at 23:59 on Tuesday 12 May 2026.\nRepresentations by providers must be submitted by 23:59 on Tuesday 12  May 2026 to: hub.psrrepresentation@nhs.net\n and must be made to the decision makers within this period.\nThe contract may be formally awarded on Wednesday 13 May 2026, provided no representations are received, or once any representations have been addressed..",
    "classification": {
      "id": "85141000",
      "scheme": "CPV",
      "description": "Services provided by medical personnel"
    },
    "procurementMethod": "limited",
    "mainProcurementCategory": "services",
    "procurementMethodDetails": "Award procedure without prior publication of a call for competition",
    "procurementMethodRationale": "Justification: Award of a contract without prior publication of a call for competition in the cases listed below\nReason: The procurement falls outside the scope of application of the regulations\nExplanation: This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act 2023 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to the relevant authority by Tuesday 12th May 2026. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.",
    "procurementMethodRationaleClassifications": [
      {
        "id": "D_PROC_OPEN",
        "scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
        "description": "No tenders or no suitable tenders/requests to participate in response to open procedure"
      }
    ]
  },
  "parties": [
    {
      "id": "GB-NHS-QKK",
      "name": "NHS South East London Integrated Care Board",
      "roles": [
        "buyer"
      ],
      "address": {
        "region": "UKI45",
        "locality": "London",
        "postalCode": "SE1 2TZ",
        "countryName": "United Kingdom",
        "streetAddress": "160 Tooley Street"
      },
      "details": {
        "url": "https://www.selondonics.org/icb/",
        "buyerProfile": "https://www.selondonics.org/icb/",
        "classifications": [
          {
            "id": "BODY_PUBLIC",
            "scheme": "TED_CA_TYPE",
            "description": "Body governed by public law"
          },
          {
            "id": "07",
            "scheme": "COFOG",
            "description": "Health"
          }
        ]
      },
      "identifier": {
        "id": "QKK",
        "scheme": "GB-NHS",
        "legalName": "NHS South East London Integrated Care Board"
      },
      "contactPoint": {
        "email": "hub.queries@nhs.net"
      }
    },
    {
      "id": "GB-NHS-CQC",
      "name": "Lambeth Healthcare Ltd",
      "roles": [
        "supplier"
      ],
      "address": {
        "region": "UKI",
        "locality": "London",
        "postalCode": "SW9 6AF",
        "countryName": "United Kingdom",
        "streetAddress": "Akerman Health Centre, Second Floor, 60 Patmos Road"
      },
      "details": {
        "url": "https://www.selondonics.org/icb/",
        "scale": "large"
      },
      "identifier": {
        "id": "CQC",
        "scheme": "GB-NHS",
        "legalName": "Lambeth Healthcare Ltd"
      },
      "contactPoint": {
        "email": "hub.queries@nhs.net"
      }
    },
    {
      "id": "GB-FTS-180912",
      "name": "NHS South East London Integrated Care Board",
      "roles": [
        "reviewBody"
      ],
      "address": {
        "locality": "London",
        "postalCode": "SE1 2TZ",
        "countryName": "United Kingdom",
        "streetAddress": "160 Tooley Street,"
      },
      "details": {
        "url": "https://www.selondonics.org/icb/"
      },
      "identifier": {
        "legalName": "NHS South East London Integrated Care Board"
      },
      "contactPoint": {
        "email": "hub.queries@nhs.net"
      }
    }
  ],
  "language": "en",
  "contracts": [
    {
      "id": "038464-2026-1",
      "value": {
        "amount": 49140,
        "currency": "GBP"
      },
      "status": "active",
      "awardID": "038464-2026-1",
      "dateSigned": "2026-04-22T00:00:00+01:00"
    }
  ],
  "description": "This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act 2023 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to decision makers by Tuesday 12th May 2026.\nThis contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.\nWritten representations should be sent to:  hub.psrrepresentation@nhs.net\nAward Decision makers: Andrew Eyres- Corporate Director, Integrated Health and Adult Social Care \nThere was no conflict of interest identified in the decision-making process.\nEvaluation Criteria and Weighting\nScoring from 0-4, with percentage allocation based on the importance of the criteria in the service requirement. Key criteria:\nQuality and Innovation: 20%\nValue for Money: 25%\nIntegration, Collaboration and Service Sustainability: 20%\nImproving Access, Reducing Health Inequalities and Facilitating Choice: 25%\nSocial Value: 10%\nThe criteria were applied with their respective weightings as specified, with scoring against a number of sub-categories for each criterion. An assessment against current and future performance for these individual sub-categories was undertaken, resulting in a combined overall score out of 100%.\nThe publication of this notice marks the start of the standstill period, commencing on Wednesday 30th April 2026 ending at 23:59 on Tuesday 12 May 2026.\nRepresentations by providers must be submitted by 23:59 on Tuesday 12  May 2026 to: hub.psrrepresentation@nhs.net\n and must be made to the decision makers within this period.\nThe contract may be formally awarded on Wednesday 13 May 2026, provided no representations are received, or once any representations have been addressed.\nThis contract has not yet formally been awarded; this notice serves as an intention to award under the Provider Selection Regime (PSR).\nNo conflicts of interest were identified in the decision-making process.\nDecision Makers and Dates of Decision\nThe decision to proceed with the intention to award was made by:\nAndrew Eyres- Corporate Director, Integrated Health and Adult Social Care \nLambeth Together Planning and Finance Group - 23 March 2026\nLambeth Together Senior Management Team - 31 March 2026\nRationale for Selection of Current Provider\nThe current provider has demonstrated sustained high-quality performance and value for money, including:\nMaintaining 100% performance across key service standards, including:\n-Provision of service to all appropriately referred patients\n-Contacting patients within 72 hours of referral from secondary care\n-Issuing patient reminder cards and information leaflets\n-Providing consistent feedback from service users and referring acute trusts\n-Reporting 0% near misses or incidents from both the provider and acute trust\n-Effective financial management, remaining within the agreed budget\n-Delivery in line with NICE TA204 (Denosumab for the prevention of osteoporotic fractures in postmenopausal women)\n-Alignment with the South East London Osteoporosis Pathway and the South East London Shared Care Agreement for Denosumab 60mg/ml\n-Supporting care closer to home and improved patient experience through community-based administration of treatment\n-Sustained achievement of ≥95% across key performance indicators, including:\n-Timely patient contact within 72 hours\n-Provision of patient information materials\n-Service user and referrer feedback mechanisms\n-Incident reporting compliance\n-Annual patient satisfaction feedback demonstrating good service experience",
  "initiationType": "tender"
}